Please sign in to follow a disease.
Mucoepidermoid carcinoma
MONDO:0003036A carcinoma morphologically characterized the presence of cuboidal mucous cells, goblet-like mucous cells, squamoid cells, cystic changes, and a fibrotic stromal formation. It can occur in several anatomic sites, including parotid gland, oral cavity, paranasal sinus, skin, breast, lung, larynx, and lacrimal ducts. It is classified as low or high grade.
Also known as: MEC, mucoepidermoid carcinoma, mucoepidermoid carcinoma (morphologic abnormality), mucoepidermoid tumor, mucoepidermoid tumour, MUCC, mucoepidermoid tumors, mucoepidermoid tumours
2741 clinical trials for this condition and its sub-types, 2 tagged with Mucoepidermoid carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Mucoepidermoid carcinoma
-
Cutaneous mucoepidermoid carcinoma 0 trials
-
Laryngeal mucoepidermoid carcinoma 0 trials
-
Mucoepidermoid breast carcinoma 0 trials
-
Mucoepidermoid esophageal carcinoma 0 trials
-
Oral cavity mucoepidermoid carcinoma 0 trials
2 sub-types
-
Pulmonary mucoepidermoid carcinoma 0 trials
1 sub-type
- Bronchus mucoepidermoid carcinoma 0 trials
-
Thymic mucoepidermoid carcinoma 0 trials
-
Trachea mucoepidermoid carcinoma 0 trials
Most studied deeper sub-types
-
Experimental drug targets Hard-to-Treat salivary gland cancers
Disease control Recruiting nowThis phase 2 trial tests whether the drug sacituzumab govitecan can help control salivary gland cancer that has come back or spread to other parts of the body. About 30 adults whose cancer cannot be removed by surgery or cured with radiation will receive the drug through an IV. R…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug combo shows promise for rare salivary gland cancer
Disease control Recruiting nowThis study tests a new drug (MRG003) alone or with another drug (putrelimab) in people with salivary gland cancer that has come back or spread. The goal is to see if these treatments can shrink tumors or stop them from growing. About 90 adults will take part, and the study is not…
Phase 2 • Sponsor: Ji Dongmei • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC